Biogen Inc. (BIIB) vs Medline Inc. (MDLN)

A side-by-side comparison of Biogen Inc. and Medline Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 10, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total returnBIIB vs MDLN

growth of $100 · dividends reinvested · last 1y
BIIB +21.3% (+21.3%/yr)MDLN -21.0% (-21.0%/yr)BIIB compounded faster over this window
8090100110120Start $1002026$121$79
BIIB MDLN

BIIB vs MDLN: by the numbers

  • BIIB is the larger company ($32.08B vs $27.51B market cap).
  • MDLN trades at the lower trailing earnings multiple (37.83 vs 38.43 P/E), one valuation lens rather than an overall verdict.
  • BIIB converts more revenue to profit (8.39% vs 2.31% net margin).

Metrics side by side

Valuation

MetricBIIBMDLN
P/E ratio38.4337.83
Forward P/E17.3921.79
P/S ratio3.230.92
P/B ratio1.702.38
EV / EBITDAN/A13.73
FCF yield8.40%4.88%

Profitability

MetricBIIBMDLN
Gross margin67.71%25.02%
Operating margin12.79%6.07%
Net margin8.39%2.31%
ROE4.43%5.97%
ROIC4.28%4.05%

Growth (annualized)

MetricBIIBMDLN
Revenue CAGR (5Y)-3.19%N/A
EPS CAGR (5Y)-18.67%N/A
FCF CAGR (5Y)-11.63%N/A
Total return CAGR (5Y)-6.40%N/A

Frequently asked

Which has the lower trailing P/E, BIIB or MDLN?
MDLN has the lower trailing P/E: BIIB trades at 38.43 and MDLN at 37.83. P/E is one valuation measure and does not by itself establish which business is cheaper.
Is BIIB or MDLN more profitable?
BIIB runs the higher net margin — BIIB at 8.39% versus MDLN at 2.31%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 10, 2026.